Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Curr Opin Immunol. 2012 Dec 6;25(2):206–213. doi: 10.1016/j.coi.2012.11.003

Figure 2. Neutralization of the Gal-1 – Gal-1 ligand axis to Boost Anti-tumor T cell Immunity.

Figure 2

(A) A schematic depiction of tumor immune evasion model in which melanoma-derived Gal-1 can antagonize the anti-tumor efficacy of T cells. (B) A cartoon depiction of the metabolic antagonism of Gal-1-binding N-acetyllactosamine synthesis in effector anti-tumor T cells caused by 4-F-GlcNAc and consequent enhancement of anti-tumor immunity. (C) A schematic overview of a novel cancer immunotherapeutic strategy to selectivity target donor CTLs with 4-F-GlcNAc for escaping Gal-1 control and improving the efficacy of adoptive T cell therapy.